Methods for Sequence Based Studies of Complex Traits. by Rashkin, Sara Rachel
  
Methods for Sequence Based Studies of Complex Traits 
 
by 
 
Sara Rachel Rashkin 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Biostatistics) 
in the University of Michigan 
2015 
 
 
 
 
Doctoral Committee: 
 
Professor Goncalo Abecasis, Chair 
Professor Michael Lee Boehnke 
Assistant Professor Hyun Min Kang 
Professor Peter Xuekun Song 
Assistant Professor Cristen J. Willer 
 
 ii  
DEDICATION 
To my family – Mom, Dad, Lee, and Hannah. 
 iii  
ACKNOWLEDGEMENTS 
The research for this dissertation was done with the help of many people, particularly Professor 
Goncalo Abecasis, Tom Blackwell, Sai Chen, Goo Jun, Alan Kwong, and Mary Kate Wing. 
 
 
 
 iv  
TABLE OF CONTENTS 
 
DEDICATION ii	  
ACKNOWLEDGEMENTS iii	  
LIST OF FIGURES vii	  
LIST OF TABLES ix	  
ABSTRACT x	  
CHAPTER I. Introduction 1	  
CHAPTER II. Optimal Sequencing Strategies for Identifying Disease-Associated Singletons
 5	  
Abstract 5	  
Introduction 6	  
Methods 8	  
Overview 8	  
Definitions 8	  
Sensitivity to Detect Singleton Variants 9	  
Power to Detect Association 11	  
Results 15	  
Sensitivity to Detect Singletons 15	  
Power to Detect Association 16	  
Discussion 18	  
vv 
Figures and Tables 21	  
CHAPTER III. Optimal Sequencing Strategies for Identifying Singletons Associated with 
Quantitative Traits 28	  
Abstract 28	  
Introduction 29	  
Methods 31	  
Overview 31	  
Definitions 31	  
Sensitivity to Detect Singleton Variants 32	  
Power to Detect Association 32	  
Results 35	  
Sensitivity to Detect Singletons 35	  
Power to Detect Association 35	  
Discussion 37	  
Figures and Tables 41	  
CHAPTER IV. Rapid Genotyping of Large Deletions from Next-Generation Sequencing 
Data 47	  
Abstract 47	  
Introduction 48	  
Methods 49	  
Results 53	  
Discussion 55	  
Figures and Tables 57	  
vivi 
CHAPTER V. Discussion 65	  
REFERENCES 67	  
 
 
 
 vii  
LIST OF FIGURES 
 
Figure II-1. Sensitivity to detect singletons by read depth, sample size, and sequencing error rate
 21	  
Figure II-2. Sensitivity to detect singletons by read depth for constant cost 22	  
Figure II-3. Comparison of empirical sensitivity to detect singletons with computational 
estimates 23	  
Figure II-4. Association study power by read depth for constant cost 24	  
Figure II-5. Association study power and NCP by read depth for constant different sequencing 
capacities 25	  
Figure II-6. Association study power and NCP by read depth for different sample preparation 
costs 26	  
Figure II-7. Association study power by read depth for fixed sample size 27	  
Figure III-1. Association study power by read depth for constant cost for different effect sizes 41	  
Figure III-2. Association study power by read depth for constant cost for varying population 
frequency of singletons 42	  
Figure III-3. Empirical power by read depth for fixed sequencing effort compared with power 
calculated via NCP 43	  
Figure III-4. Association study power and NCP by read depth for different total costs 44	  
Figure III-5. Association study power and NCP by read depth for different library/sample 
preparation costs 45	  
viiiviii 
Figure III-6. Association study power by read depth for fixed sample size 46	  
Figure IV-1. Example of region where distributions are well-separated 57	  
Figure IV-2. Example of regions where distributions are very overlapped 60	  
Figure IV-3. Example of a region where read counts do not follow expected distribution 61	  
Figure IV-4. Example of region where distributions are overlapping 62	  
Figure IV-5. Concordance after Genotype Refinement vs. Original Concordance 63	  
Figure IV-6. Venn diagram comparing lists of regions identified in each dataset 64	  
 
 
 
 
 ix  
LIST OF TABLES 
 
Table IV-A. Region concordance by KL threshold 58	  
Table IV-B. Region concordance by KL threshold for regions where μ2-2σ<0 59	  
 
 
 x  
ABSTRACT 
 
Thousands of loci have been associated with complex diseases and traits. However, there is still 
much we do not know about the biology of disease. Many reasons for this are possible, including 
the strong focus of genetic association studies over the past 5-10 years on common single 
nucleotide polymorphisms. In this dissertation, we focus on methods for the design and analysis 
of sequence based studies, to enable the assessment of other types of variants, particularly rare 
variants and copy number variants. 
 
In the first chapter, we attempt to resolve the debate regarding the best strategy for studying very 
rare, disease-associated variants, particularly singleton variants appearing only once in a sample. 
We estimated the sensitivity to detect singleton variants using both simulations and analysis of 
real data. We extended this to determine the power of an association study for discrete traits, 
evaluating the burden of singletons under a variety of situations. We found that sensitivity to 
detect singletons increases with sequencing depth, plateauing when depth reaches ~25x. For a 
fixed sequencing capacity, we estimated that power is maximized when samples are sequenced at 
15-20x coverage, which produced an optimal trade-off of singleton discovery and sample size. In 
our assessments, increasing coverage beyond 15-20x (and decreasing sample size) results in 
reduced power. 
 
xixi 
In the second chapter, we extend this analysis to a quantitative trait framework. Despite the 
different disease model, the results for quantitative traits are remarkably similar to those for 
binary traits. For constant sequencing effort, power is maximized at 11-16x coverage, for a 
variety of parameter values examined. Increasing coverage further for reduced sample size 
results in decreased power. 
 
In the final chapter, we turn to another type of variant that may aid in understanding the etiology 
of disease: copy number variation. Copy number variants (CNVs) are associated with many 
diseases, especially psychiatric disorders, and there is great interest in methods to accurately 
detect and genotype CNVs. We developed a method that uses read depth information to estimate 
copy number for a set of sequenced individuals. 
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CHAPTER I. Introduction 
 
One aim of genetic association studies is to further our mechanistic understanding of genetic 
diseases: knowing which genes are associated with disease can be used to determine functional 
pathways leading to disease.1 Much work has been done to study the impact of genetic variation 
on human disease. In recent years, genome-wide association studies (GWAS) have allowed for 
testing of millions of variants simultaneously.2; 3 This has made it possible to identify thousands 
of loci related to diverse diseases.3; 4 Ultimately, we want to translate association signals to 
function, and studies have resulted in some key insights.4 Despite this progress, however, there is 
still much we do not understand about the functional mechanism of disease.1; 4 
 
It is believed that rare variants may prove particularly useful in further elucidating etiology of 
disease.5; 6 A strong focus of genetic association studies in the past has been on common single 
nucleotide polymorphisms (SNPs).3; 7; 8 While many common variants have been associated with 
diseases, most convey only a small increase in disease susceptibility – not enough to fully 
explain the proportion of phenotypic variance explained by genetic factors.2; 3; 7; 8 Rare variants 
are more likely to be functional4-7; 9; 10 and have large effect sizes7; 9; 10, which point to key 
locations necessary for proper function. Therefore, rare variant association studies have been 
expanding rapidly. Examples of recent discoveries include: four low-frequency or rare variants 
associated with risk of type 2 diabetes, including a rare variant with minor allele frequency 
(MAF) of 0.20% (odds ratio of 2.27)11; a rare variant associated with increased risk of prostate 
22 
cancer (odds ratio of 2.90)12; and a very rare mutation with MAF 0.0076% associated with 
increased risk of schizophrenia (odds ratio 7.1).13 
 
While it is now clear that rare variants increase disease susceptibility for many diseases, there is 
still much debate regarding the best way to identify these variants.4 In particular, the popular 
theory is that deep sequencing is necessary to obtain a complete catalog of variation.4; 10 
However, some studies have shown that, especially for large sample sizes, many rare variants 
can be detected at low sequencing depth.3; 4; 14 Additionally, in most studies, there is a trade-off 
between sample size and sequencing depth so that, to maintain constant cost, if one increases, the 
other must decrease. Therefore, deep sequencing often requires reducing sample size.3; 4 While 
sequencing at greater depth may increase sensitivity to detect variants, association study power 
tends to increase with sample size. As a result, it is still unclear what is the ideal sequencing 
strategy for studying rare variants. 
 
We focused on singleton variants (those that appear only once in a sample), as designs that work 
well for them will likely provide an upper bound of needed sequencing depth for more common 
variants, for which low pass data can be analyzed more effectively.3; 15 We examined the balance 
between the sensitivity to detect singletons with association study power under a variety of 
situations in order to identify optimal study designs. We calculated the sensitivity to detect 
singletons at different sample sizes and read depths using both simulations and real data. We 
then used these estimates to assess association study power for a discrete trait under various 
conditions. We found that association study power is maximized at 15-20x coverage for a variety 
of trait models and study designs examined. 
33 
 
Another area of intense focus in recent years is studies of quantitative traits. Quantitative traits 
are frequently associated with disease (ie: cholesterol levels with heart disease, glucose levels 
with diabetes) and can, therefore, be used as markers for disease. This allows for a more flexible 
method of analysis. Additionally, knowledge of how genetic variation affects quantitative traits 
can aid in our understanding the mechanistic cause of disease.16 For instance, knowing a variant 
is associated with increased cholesterol, which increases the risk of heart disease, tells us how 
that variant leads to increased risk of heart disease. We extended our analysis to consider the 
association of singleton variants with quantitative traits. We found that 11-16x coverage results 
in maximal power for the trait models and study designs we considered. 
 
In addition to rare variants, a better functional understanding of the biology of disease may also 
lay beyond single nucleotide polymorphisms (SNPs).2; 8; 17 Copy number variants (CNVs) have 
been associated with a number of diseases, particularly psychiatric disorders such as 
schizophrenia and autism.18-20 It is necessary to have a reliable way of detecting such variants.  
 
Historically, array-based methods have been used to locate CNVs – specifically array 
Comparative Genomic Hybridization (aCGH) – but these methods do not allow for other types of 
analyses.20 As sequencing becomes cheaper, using sequence data to determine copy number 
becomes an attractive approach, as this allows for saving the cost of aCGH and allows for other 
types of analyses to be performed simultaneously. A number of methods have been devised to 
perform such an analysis, but most analyze one sample at a time.21 We developed a quick, easy 
44 
to use, and accurate method that determines copy number within a particular, well-defined region 
of interest for a sample of individuals. 
 
In this dissertation, we describe methods that will aid in the design and analysis of complex traits 
using sequence data. We begin by determining optimal designs for studying singleton variants 
related to discrete traits. We then extend this to ascertain the ideal strategy for studying 
singletons associated with quantitative traits. Finally, we propose a novel method for detecting 
copy number variants from sequence data. 
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CHAPTER II. Optimal Sequencing Strategies for Identifying Disease-Associated 
Singletons1 
 
Abstract 
With the increasing focus of genetic association on the identification of trait-associated rare 
variants, it is important to identify the most cost-effective sequencing strategies for these studies. 
Deep sequencing will accurately detect and genotype the most rare variants per individual, but 
may limit sample size. Low pass sequencing will miss some variants in each individual but has 
been shown to provide a cost effective alternative for studies of common variants. Here, we 
investigate the impact of sequencing depth on studies of rare variants, focusing on singletons - 
the variants that are sampled in a single individual and are hardest to detect at low sequencing 
depths. We first estimate the sensitivity to detect singleton variants in both simulated data and in 
down-sampled deep genome and exome sequence data. We then explore the power of association 
studies comparing burden of singleton variants in cases and controls under a variety of 
conditions. We show that the power to detect singletons increases with coverage, typically 
plateauing for coverage > ~25x. Next, we show that, when total sequencing capacity is fixed, the 
power of association studies focused on singletons is typically maximized for coverage of 15-
20x, independent of relative risk, disease prevalence, singleton burden, and case-control ratio. 
                                                
1 Rashkin, S., Jun, G., Chen, S., Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), and 
Abecasis, G. (In preparation). Optimal Sequencing Strategies for Identifying Disease-Associated Singletons. 
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Our results suggest sequencing depth of 15-20x as an appropriate compromise of singleton 
detection power and sample size for studies of rare variants in complex disease. 
 
Introduction 
New sequencing technologies are shifting the focus of genetic association studies to rare 
variants. Rare variants may explain much of the heritability of common, complex diseases.6; 10 
Importantly, rare variants are more likely to severely disrupt gene function5; 6, and identifying 
trait associated rare variants may accelerate progress from genetic association signals to 
mechanistic understanding of disease. 
 
It is frequently asserted that the study of rare variants requires deep sequencing, which provides 
the highest power for variant discovery in any single genome.4; 10 The alternative of low-pass 
sequencing has been advocated for studies of common variation,3; 14 supported by empirical 
studies.22 Low pass sequencing allows for larger sample sizes but misses some variants in each 
individual and reduces genotyping accuracy.3; 4 The 1000 Genomes Project used low pass 
sequencing of ~2,500 individuals to catalog genetic variation and haplotypes across 26 
populations.14 The project has produced a near complete catalog of common variation but also 
identified many rare variants, including singletons, in sequenced individuals.  
 
We speculated that low pass or intermediate depth sequencing could be useful even for studies of 
very rare variants. It is now clear that these studies often require large sample sizes, totaling 
thousands of individuals. Examples of successful rare variant association studies include several 
studies implicating rare variants in the complement genes (CFH, C3, CFI, C9) in the risk of age-
77 
related macular degeneration,23-26 a study showing rare IFIH1 variants protect against type 1 
diabetes,27 and a study that found that rare variants that inactivate NPC1L1 reduce the risk of 
coronary heart disease.28  
 
Here, we attempt a more nuanced view of the optimal strategies for sequence based rare variant 
association studies and explore and compare the power of rare variant association studies that use 
low, intermediate, or deep sequencing strategies. Since common variants can be detected and 
genotyped efficiently by analyzing sequence data for many individuals jointly, we focused our 
analysis on singletons. Any sequencing depth that works well for singletons should provide an 
upper bound of needed sequencing depth for more common variants, for which low pass data can 
be analyzed more effectively.3; 15 In this paper, we examine discrete traits and seek to maximize 
association study power for a fixed sequencing effort (in a companion manuscript, we explore 
quantitative traits29). We consider the balance between power to identify very rare variants 
(which increases with sequencing depth) and power to identify disease association (which 
increases with sample size). We explore both simulated data and actual sequence data. We 
estimate the power of association tests for study designs employing deep sequencing, low pass 
sequencing, and intermediate strategies across a range of sample sizes, singleton frequencies, 
disease relative risks, and disease prevalence. Our results show that, for fixed cost, power to 
detect association is maximized at a read depth of 15-20x and decreases rapidly as coverage is 
increased beyond this threshold. 
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Methods 
Overview 
To determine the ideal study design for studying disease-related singletons, we first used 
simulations to explore the ability to detect singleton variants present in sequenced samples. Next, 
we validated simulations by comparing results to down-sampled sequence data. Finally, we 
extended these analyses of variant discovery power to examine association study power. 
 
Definitions 
We consider sequencing studies that assess N individuals, sequencing each to an average depth d. 
We assume that the cost of the study is proportional to the cost of preparing samples for 
sequencing, Nc, and the total sequencing depth, Nd. (Here, c is a constant that places sequencing 
depth and per sample cost in the same scale).  
 
Thus, we estimate the total cost of a sequencing study as: 
€ 
Cost = N ⋅ cost per sample( )
= N ⋅ d⋅ cost per depth( ) + N ⋅ cost of library and sample preparation( )
= N ⋅ cost per depth( )⋅ d + c( )
∝ N ⋅ c + d( )  
where N(c+d) is the total sequencing capacity. In this simple model, to keep total cost constant, 
sample size and depth must vary inversely of each other (i.e., if sample size increases, coverage 
decreases). In our simulations, we first considered c=0. We then expanded our analyses to also 
consider c=5 and c=20 for total budgets of sequencing capacity = 50,000x, 100,000x, and 
200,000x. With current genome sequencing costs of $1,000 - $3,000 per 30x genome, c=5 and 
99 
c=20 correspond to costs of ~$250 to $600 and of ~$700 - $2,000 for sample collection and 
preparation, respectively. 
 
Sensitivity to Detect Singleton Variants 
We first used simulations to estimate the sensitivity of singleton discovery. We ran these 
simulations using different read depths (d, ranging from 2x to 50x), sample sizes (N, ranging 
from 100 to 5,000), sequencing error rates (e, ranging from 0.001 to 0.02) and singleton 
discovery false positive rates (γ, 0.00001, 0.0001, 0.001, 0.01, and 0.05). For each combination 
of parameters, we generated 200,000 replicate samples, each with a single individual carrying the 
simulated singleton variant (when estimating sensitivity) or no individuals carrying the variant 
(when estimating false positive rates).  
 
We assumed read depth followed a Poisson distribution. For each individual, we track the total 
number of sequencing reads as well as the number of reads in which a variant base was observed. 
For each individual, depth was generated from Poisson(d), and each read was generated with a 
sequencing error occurring with probability e. Briefly, our simulation proceeded as follows. We 
first sampled a total read depth for each individual and set the number of variant reads to zero. 
Then, for each read, we select a strand at random. Then, we increased the number of variant 
reads whenever the simulated read was assigned to the individual and strand that has the 
singleton variant (without a sequencing error, probability 1 - e) or when the simulated read was 
assigned to a different individual (but with a sequencing error, probability e). We then estimate 
the likelihood of the observed count of variant reads, conditional on depth and sequencing error 
rates and an allele frequency; first, assuming that all individuals match the reference so that the 
1010 
number of variant reads in each individual is distributed as Binomial(Prob = e, Count = depth); 
next assuming that a rare variant is segregating with frequency 1/2N, so that the number of 
variant reads is distributed as (1 – 1/2N) x Binomial(Prob = e, Count = depth) + 1/2N x 
Binomial(Prob = 0.5, Count = depth). Finally, we take the ratio of these two likelihoods. The 
sensitivity for detecting a variant with false positive rate γ was computed as the fraction of 
simulations with a simulated singleton for which the likelihood ratio was greater than the (1- γ)th 
percentile of null simulations using the same sample size, depth, and sequencing error rate 
parameters.  
 
We validated these estimates by down-sampling on chromosome 20 from deep genome and 
exome samples and assessing the sensitivity to detect singletons called when all available 
sequence data was analyzed. Exome samples are from the NHLBI Exome Sequencing Project6; 30 
(original depth of exome sequenced regions in chromosome 20 averaging 106.80x, range 27.10–
515.25x). We excluded samples with an average depth <50x to allow for down-sampling to 
depths 2-50x. Whole genome samples are from the Genetics and Epidemiology of Colorectal 
Cancer Consortium31 (original depth averaging 35.79x, range 30.35-42.59x). For whole genome 
samples, we considered down-sampled depths 2-30x. In each down-sampling analysis, we 
sampled reads from each individual to create a new sample with the desired average depth. For 
instance, for an individual with an original depth of 100x, we would retain each of the original 
reads with a probability of 10% to achieve depth 10x.  
 
After down-sampling, we performed variant calling using SAMtools mpileup.32 Sensitivity for 
each subsample was computed as the proportion of singletons in the original deep sequence data 
1111 
that were called in the down-sampled data. The false positive rate was estimated as the 
proportion of sites where variants were called in the down-sampled data but not in the original 
deep sequence data. We averaged the results of 100 replications for 100 individuals at each depth 
(each exome replicate examined 788,942 bases on chromosome 20 and included 126-231 
singletons; each whole genome replicate examined 63,025,520 bases on chromosome 20 and 
included 75,269-79,849 singletons). 
 
We chose parameter settings for computational simulations so that results closely mimicked 
those for analysis of down-sampled real data. We then used these values in the analysis of 
association study power across a broad range of sample sizes, sequencing depths, and cost 
models.  
 
Power to Detect Association 
We estimated association study power analytically by comparing the burden of singletons in a 
region between cases and controls, at significance level α = 2.5x10-6, corresponding to the 
analysis of ~20,000 independent gene regions. Power for a two-sample t-test can be estimated 
using a non-central t-distribution to model test statistics as a function of sample size, the 
frequency of singleton variants per gene per person, the increased risk of disease conveyed by a 
singleton variant, and the sensitivity to detect each singleton (which is a function of sequencing 
depth). 
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Modeling this non-central t-distribution requires estimates of a non-centrality parameter λ, which 
describes the expected value of the statistic for a given disease model and experimental design. 
The requisite non-centrality parameter λ for a two-sample t-test can be expressed as: 
€ 
λ =
µA − µU
σA
2 NA +σU2 NU
 
where μA is the mean number of singletons per gene per person in affected individuals, and σA2 is 
the corresponding variance. Similarly, μU and σU2 are the mean and variance for unaffected 
individuals. NA and NU are the number of affected and unaffected individuals, respectively.  
 
We assume that the number of singletons occurring per gene per person follows a Poisson 
distribution with rate parameter equal to the product of gene length (L) and frequency of 
singleton occurrence per site per person for cases (pA) or controls (pU). For a subset of 
simulations, we compared results of a two-sample t-test and a Wilcoxon rank-sum test. Since 
both gave similar results, we proceeded with the two-sample t-test.  
 
The non-centrality parameter can be expanded as: 
€ 
λ =
L⋅ pA − L⋅ pU
L⋅ pA NA + L⋅ pU NU  
Here, pA and pU are the cumulative frequencies of singletons among cases and controls (for 
deeply sequenced samples). For low and intermediate sequencing depths, we replace these with 
pA* and pU*, which are the frequency of detected singletons in cases and controls at a given 
sequencing depth. These quantities can be defined as: 
1313 
€ 
pA* = P detect singleton | d, N, case( )
= P detect singleton | singleton, d, N( )⋅ P singleton | case( )
+ P detect singleton | no singleton, d, N( )⋅ P no singleton | case( )
pU* = P detect singleton | d, N, control( )
= P detect singleton | singleton, d, N( )⋅ P singleton | control( )
+ P detect singleton | no singleton, d, N( )⋅ P no singleton | control( )
 
where P(detect singleton | singleton, d, N) is the sensitivity to detect singleton variants for a 
given read depth and sample size, and P(detect singleton | no singleton, d, N) is the 
corresponding false positive rate. The frequency of singleton occurrence in cases and controls 
can be expressed as: 
€ 
P singleton | case( ) = prf /Lprf /L + (1− p /L) f =
pr /L
pr /L + (1− p /L)
P singleton | control( ) = p /L(rp /L +1− p /L − rf )(1− f )(rp /L +1− p /L)
 
where r is relative risk of disease (ranging from 2 to 20 in our simulations), p is population 
frequency of singletons (ranging from 0.001% to 1% per gene per person in our simulations), L 
is gene length (ranging from 1,000 to 50,000 bps in our simulations), and f is the background 
prevalence of disease (ranging from 0.1% to 20% in our simulations). We considered different 
case-control ratios (1:1, 2:1, 3:1, and 1:2 in our simulations). 
 
We considered prevalences from 0.1% to 20% to explore scenarios for studying different 
diseases. Such diseases include very complex diseases such as cardiovascular disease, which has 
a prevalence of 33% in American adults33, intermediate frequency diseases such as age-related 
macular degeneration, which has an estimated prevalence of 1.47% in Americans 40 years and 
1414 
older34, but also less common diseases such as type 1 diabetes, which has an approximate 
prevalence of 0.33% in Americans 18 years and younger35.  
 
From our exome samples, we estimated that singletons occur at a rate of 0.79% per gene per 
person for the entire genome (assuming approximately 20,000 genes). This rate fluctuates when 
looking at specific genes. Longer genes are more likely to include singletons than shorter genes. 
For instance, AVP (a gene that provides instructions for making the hormone vasopressin) is 
2,169 bp long36 and has an estimated frequency of singletons of 0.058% per person in the coding 
region, while TTN (encoding a giant muscle protein that plays a key role in muscle assembly and 
one of the longest genes in the human genome) is 281,435 bp long37 and has a singleton 
frequency of 42% per person in the coding region. Genes of different functions might have 
different frequencies of singletons. We varied population frequency of singletons from 0.001% 
to 1% per gene per person to account for this wide set of possibilities.  
 
Once the non-centrality parameter is computed, the power of an association test can be estimated 
by: 
€ 
Power = P X > tα / 2(ν, 0) | X ~ t(ν, λ)( )
where
tα / 2(ν, 0) =100(1−α /2) percentile of the central
t with ν degrees of freedom
t(ν, λ) = Non − central t with ν degrees of
freedom and non − centrality parameter λ
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Results 
Sensitivity to Detect Singletons 
Our simulations show that, for a fixed sample size, sensitivity to detect singletons increases 
rapidly as coverage increases until ~25x (see Figure II-1a). After this point, increasing coverage 
has little effect on sensitivity. As sample size increases for a fixed depth, sensitivity decreases 
only slightly (see Figure II-1b), implying that coverage at a site has more impact than sample 
size in the overall ability to detect singletons. For constant depth and sample size, an increase in 
sequencing error rate reduces sensitivity (see Figure II-1c). At higher false positive rates, 
sensitivity is greater (see Figure II-1), although the number of incorrectly called singletons 
increases as well. Among the settings we considered, by 25x, sensitivity reaches 98.6% for a 
sequencing error rate of 0.005, 96.2% for an error rate of 0.01, and 89.9% for a sequencing error 
rate of 0.02, regardless of sample size or false positive rate. Increasing depth to 30x resulted in 
sensitivity of 99.6% for a sequencing error rate of 0.005, 98.8% for an error rate of 0.01, and 
95.9% for an error rate of 0.02. Further increase in depth to 50x, resulted in 100% sensitivity, 
regardless of error rate.   
 
As shown in Figure II-1, variant detection sensitivity changes rapidly with read depth but only 
very slowly with sample size (sensitivity decreases slightly with increased sample size because, 
when depth and total false positive rate are fixed, the caller must become gradually more 
stringent as more samples are sequenced so as to maintain a fixed false-positive rate). We next 
explored variant discovery power in experiments with constant cost, where sample size and read 
depth vary in opposite directions. We first considered a simplified case with no additional cost 
for library and sample preparation, so that read depth and sample size are inversely proportional. 
1616 
In this case, as coverage increased, sensitivity increased until 20-25x, after which increasing read 
depth had little effect on sensitivity (see Figure II-2). When we varied the total sequencing 
capacity, there was little difference between the sensitivity to detect singletons at a fixed read 
depth, emphasizing that read depth has more effect than sample size on sensitivity. For instance, 
at 10x coverage, sequencing 5,000 samples provides 64% sensitivity, sequencing 10,000 samples 
provides 60.8% sensitivity, and sequencing 20,000 samples provides 57.9% sensitivity; whereas, 
at 20x coverage, sequencing 5,000 samples provides 97.4% sensitivity, sequencing 10,000 
samples provides 96.8% sensitivity, and sequencing 20,000 samples provides 96.1% sensitivity. 
 
Analyses of down-sampled data validated our computational simulations (see Figure II-3). For a 
fixed sample size of 100 individuals, empirical estimates of sensitivity closely resemble 
simulations that assume a sequencing error rate of 0.01 and a false positive rate of 0.001, though 
the simulations were slightly conservative at lower depth – detecting a lower proportion of 
variants than in the down-sampled data – and slightly anti-conservative at higher depth – 
detecting a larger fraction of variants than in the down-sampled data with the same total depth 
(see Figure II-3). We thus used e = 0.01 and γ = 0.001 to estimate variant detection sensitivity 
and assess association study power for a broad range of cost models and sequencing capacities.   
 
Power to Detect Association 
We first considered a situation of fixed cost (sample size and read depth vary inversely) with no 
extra cost of library/sample preparation (c=0) for equal numbers of affected and unaffected 
individuals. As depth increases, association study power quickly reaches a maximum and then 
rapidly decreases (see Figure II-4). For example, sequencing 20,000 samples at 5x provides only 
1717 
1.19% power, sequencing 6,666 samples at 15x provides 91.08% power, and sequencing 2,000 
samples at 50x provides 17.71% power for a relative risk of 15, population frequency of 
singletons 0.01 per person per gene, and a prevalence of 20%. Maximum power increases with 
relative risk, population frequency of singletons, or prevalence (see Figure II-4a-c). For unequal 
numbers of cases and controls, power decreases as the case-control ratio moves further away 
from 1:1 (see Figure II-4d).  
 
When the NCP is large, a change in the NCP might not be reflected in power if the power is 
already 1. Therefore, we examined the read depth/sample size pair where the maximum NCP, 
rather than power, was attained. The depth at which the NCP is maximized occurs between 15-
20x depending on study cost and the relative cost of library/sample preparation. As available 
sequencing capacity and total study cost increase, the maximum NCP increases (see Figure II-5). 
As relative cost of library/sample preparation (c) increases, NCP decreases slightly (see Figure 
II-6). When either total study cost or c increases, the point at which NCP is maximized shifts to a 
higher depth. For c=0, NCP is maximized at 15-16x; for c=5, NCP is maximized at 16-18x; and 
for c=20, NCP is maximized at 18-19x. For sequencing capacity=50,000x, NCP is maximized at 
15-18x; for sequencing capacity=100,000x, NCP is maximized at 16-18x; and, for sequencing 
capacity=200,000x, NCP is maximized at 16-19x. This point is not affected much by relative 
risk, prevalence, population frequency of singletons, or gene length. The overall pattern is easy 
to understand intuitively: with increasing per sample preparation costs, it is advantageous to 
sequence fewer samples at higher depth; with increasing total sequencing capacity, the overall 
sample size increases and a slight increase in sequencing depth is needed to accommodate the 
greater stringency needed to maintain low false positive rates in variant calling.  
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For fixed sample size, increasing coverage is never harmful. At lower depth, increasing coverage 
increases association study power; at high depths, power eventually plateaus (see Figure II-7). 
For instance, for relative risk of 15, population frequency of singletons 0.008, and prevalence 
0.2, sequencing 10,000 samples provides 30.45% power at 10x, 97.99% power at 25x, 98.27% 
power at 35x, and 98.27% power at 50x. For increased sample size, relative risk, population 
frequency of singletons, or prevalence, the magnitude of power increases. Regardless of the 
parameter values, NCP is maximized by 35x, with 99% of maximal NCP occurring by 25x. 
 
Discussion 
We set out to identify ideal sequencing strategies, in terms of read depth and sample size, 
focusing on studies exploring the association of singleton variants and discrete traits.  We found 
that association study power is never large unless frequency of singletons or relative risk is large. 
When cost is fixed so sample size varies inversely of read depth, power decreased as coverage 
increased beyond 15-20x. Even for fixed sample size, increasing coverage beyond 25x had only 
a small impact on power. Therefore, we believe it will often be better to sequence larger samples 
at lower coverage rather than smaller samples at increased coverage when searching for disease 
associated singletons. We recommend that coverage should only be increased beyond 20x if 
sample numbers are limited or if applications other than genetic association studies (such as 
genetic counseling and diagnosis) can justify the advantages of more complete sequencing of 
each individual at the cost of reduced sample sizes. 
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While varying prevalence, singleton frequency, and relative risk varies association study power, 
the combination of read depth and sample size combination that maximizes power (for a fixed 
cost) remained constant. For example, consider two scenarios. The first has a relative risk of 10, 
a prevalence of 20%, and a population frequency of singletons of 0.8%. The other has a relative 
risk of 12.5, a prevalence of 20%, and a population frequency of singletons of 1%. Both 
scenarios have a sequencing capacity of 200,000x with intermediate library and sample 
preparation costs (c=5) and a gene length of 1000 bp. The first scenario attains a maximum 
power of 19.87% (NCP = 3.86); the second reaches a maximum power of 92.07% (NCP = 6.12). 
However, in both cases, NCP is maximized at a depth of 18x (with 8,695 samples). This suggests 
that deep sequencing is not justified for detecting rare variant association, irrespective of the 
disease or gene under study. While power may be low, increasing coverage beyond a threshold at 
15-20x will not increase power if it requires a decrease in sample size. For more common 
variants, there is likely even higher sensitivity for detecting variants at lower depths, so we 
expect association study power will be maximized at even lower coverage.3 
 
Of the parameters we considered, only the cost of library and sample preparation changed the 
depth required to maximize association study power, though this optimal depth remained 
between 15-20x. For larger library and sample preparation costs, the optimal depth increases 
slightly. For no extra cost of library/sample preparation (c=0), the ideal depth is 15-16x; for a 
moderate cost of library/sample preparation (c=5), the ideal depth is 16-18x; and when the cost 
of library/sample preparation is high (c=20), the ideal depth is 18-19x. When there is an 
increased penalty for increasing sample size rather than increasing coverage in the current 
sample, a slightly deeper coverage is ideal to compensate for this penalty. For very large studies, 
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the ideal depth shifts to slightly larger depths. For example, when the total sequencing capacity is 
50,000x, the ideal depth is 15-18x per genome; when this increases to 100,000x, the ideal depth 
is 16-18x per genome; and, for sequencing capacity of 200,000x, the ideal depth is 16-19x per 
genome. This increase in per genome depth allows variant calling to become more stringent as 
sample size increases (there are more opportunities for false positive calls as more genomes are 
sequenced). 
 
In summary, we have shown that, while deep sequencing is appealing for detecting a complete 
catalog of variants, increasing sample size at the cost of lower depth of coverage per sample 
results in higher power for association studies. An avenue of future work is to conduct a similar 
analysis for quantitative traits.29 Additionally, our simulations focus on SNPs, but other types of 
variants such as insertions and deletions are of interest. These non-SNP variants are typically 
more difficult to detect than SNPs,38 and may justify higher coverage to enable accurate 
genotyping followed by detection of association. 
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Figures and Tables 
Figure II-1. Sensitivity to detect singletons by read depth, sample size, and sequencing 
error rate 
Sensitivity vs. (a) read depth for N=1000 and e=0.01, (b) sample size for d=10x and e=0.01, and 
(c) sequencing error rate for N=1000 and d=10x at different false positive rates. 
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Figure II-2. Sensitivity to detect singletons by read depth for constant cost 
Comparing computational simulations (for a sequencing capacity of 50,000x) for sensitivity to 
detect singletons for different false positive rates shows that power increases until 25-30x, exact 
threshold increasing with increased error rate or decreased false positive rate. (Sample size = 
cost/depth, assuming no cost of library/sample preparation, c=0) 
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Figure II-3. Comparison of empirical sensitivity to detect singletons with computational 
estimates 
For a sample size of 100, sequencing error rate of 0.01 with a false positive rate of 0.001, 
empirical and computational estimates are similar. 
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Figure II-4. Association study power by read depth for constant cost 
Power of an association study increases with relative risk (a), population frequency of singletons 
(b), prevalence (c), and ratio of cases to controls (d) for a fixed sequencing capacity of 100,000x 
with no extra cost for library/sample preparation (c=0).  
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Figure II-5. Association study power and NCP by read depth for constant different 
sequencing capacities 
Library/sample preparation costs low (c=0), relative risk 15, population frequency of singletons 
0.01, prevalence 20%, case-control ratio 1:1 
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Figure II-6. Association study power and NCP by read depth for different sample 
preparation costs 
Sequencing capacity 100,000x, relative risk 15, population frequency of singletons 0.008, 
prevalence 20%, case-control ratio 1:1 
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Figure II-7. Association study power by read depth for fixed sample size 
Increasing coverage beyond a threshold does not increase power of an association study for 
constant sample size. 
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CHAPTER III. Optimal Sequencing Strategies for Identifying Singletons Associated with 
Quantitative Traits2 
 
Abstract 
A major focus of modern genetic association studies is the effect of rare variation on quantitative 
traits, so it is important to determine cost-effective sequencing strategies for these studies. Deep 
sequencing allows for accurate detection and genotyping of all variants per individual, but may 
restrict sample size. The reduced cost of low-pass sequencing allows for increased sample sizes 
(given a fixed total cost), which is beneficial in association studies, but may miss some variants. 
Here, we explore the effect of sample size and depth on studies of rare variants associated with 
quantitative traits, focusing on singleton variants that appear in a single individual in a sample 
and are the most difficult type of variant to detect. We examined the sensitivity to detect 
singletons in simulated data and down-sampled deep genome and exome data. We extended this 
to examine association study power comparing the burden of singletons in a gene to the trait 
value. We show that when sequencing capacity is fixed, power of association studies focused on 
singletons is typically maximized for 11-16x coverage, independent of frequency of singletons 
per gene per person and effect size. Our results suggest a sequencing depth of 11-16x as an 
appropriate compromise of sample size and sequencing depth for studies of rare variants and 
quantitative traits. 
                                                
2 Rashkin, S., Jun, G., and Abecasis, G. (In preparation). Optimal Sequencing Strategies for Identifying Singletons 
Associated with Quantitative Traits. 
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Introduction 
Quantitative traits have become an area of intense focus in recent years.16 Examples of 
quantitative traits include height, cholesterol levels, and blood glucose levels. Frequently, these 
can be used as markers for a disease, and they can also aid in understanding the basic mechanism 
of disease.16 Knowing how variants affect a quantitative trait value can be informative about the 
biological mechanism by which that variant affects disease, rather than simply knowing that a 
variant increases or decreases disease susceptibility. 
 
As with binary traits, there is still much we do not know about the biological basis of quantitative 
traits.4; 16 Focusing entirely on common single nucleotide polymorphisms (SNPs) is insufficient 
for understanding the biology of quantitative trait variation.2; 4; 8; 16 Rare variants are more likely 
to disrupt gene function and might, therefore, explain some of missing heritability of common, 
complex diseases and increase our mechanistic understanding of disease.4-7 With the advent of 
better sequencing technologies, allowing for reduced costs of sequencing studies, it is possible to 
include rare variants in genetic association studies. 
 
A typical study design for examining rare variants relies on deep sequencing to provide the 
highest power for variant discovery.4; 10 However, deep sequencing increases the cost of 
sequencing a single sample, limiting the number of individuals for a sequencing study (given 
fixed resources), which typically reduces the power to detect association. Lower coverage can 
reduce sequencing costs but may result in missing many rare variants.3; 39 Recent studies have 
shown that rare variants can be detected even with low coverage sequencing if the sample size is 
3030 
large.3; 4; 14 Examples of such studies have identified rare variants including an LDLR variant that 
is associated with low-density lipoprotein cholesterol levels40 and several rare and low-frequency 
variants associated with hematological traits41. These results imply that a detailed comparison of 
sequencing study designs for the specific purpose of studying rare variants associated with 
quantitative traits is useful for designing modern genetic studies.  
 
Here, we compare the power of sequencing based rare variant association studies using low, 
intermediate, and deep sequencing strategies. Since singleton variants that appear only once in a 
sample are the most difficult type of variant to detect, designs with power to detect associations 
between them and a trait value should have power to detect associations with a trait for more 
common variants. Any sequencing depth that works well for singletons should provide an upper 
bound of needed sequencing depth for more common variants, for which low pass data can be 
analyzed more effectively.3; 15 Our goal was to determine optimal sequencing strategies that 
maximize power for a fixed sequencing effort for studies exploring the role of singletons in 
quantitative traits (we conducted a similar analysis for binary traits in a companion paper42).  
 
We examined the balance between sensitivity to detect singletons (increases with coverage) and 
power to detect association (increases with sample size) with analyses using simulated data and 
actual sequencing data. We explored the power of association tests for study designs 
implementing low, intermediate, and deep sequencing strategies across a range of effect sizes 
and frequencies of singletons. Our results show that, for fixed sequencing capacity, power to 
detect association is maximized at 11-16x and decreases as coverage is increased beyond this 
threshold. 
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Methods 
Overview 
To determine the optimal study design for studying singletons associated with quantitative traits, 
we conducted several simulations under a variety of parameter values. We approximated 
sensitivity to detect singletons by computational simulations validated by simulations using real 
data. We then extended these results to examine how association study power varies under 
different study designs in terms of sample size and read depth. 
 
Definitions 
We consider sequencing studies that assess N individuals, sequencing each to an average depth d. 
We assume that the cost of the study is proportional to the cost of preparing samples for 
sequencing, Nc, and the total sequencing depth, Nd. (Here, c is a constant that places sequencing 
depth and per sample cost in the same scale).  
 
Thus, we estimate the total cost of a sequencing study as: 
€ 
Cost = N ⋅ cost per sample( )
= N ⋅ d⋅ cost per depth( ) + N ⋅ cost of library and sample preparation( )
= N ⋅ cost per depth( )⋅ d + c( )
∝ N ⋅ c + d( )
 
where N(c+d) is the total sequencing capacity. In this simple model, to keep total cost constant, 
sample size and depth must vary inversely of each other (i.e., if sample size increases, coverage 
decreases). In our simulations, we first considered c=0. We then expanded our analyses to also 
consider c=5 and c=20 for total budgets of sequencing capacity = 50,000x, 100,000x, and 
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200,000x. With current genome sequencing costs of $1,000 - $3,000 per 30x genome, c=5 and 
c=20 correspond to costs of ~$250 to $600 and of ~$700 - $2,000 for sample collection and 
preparation, respectively. 
 
Sensitivity to Detect Singleton Variants 
We first implemented computational simulations to estimate the sensitivity of singleton 
discovery. For each combination of depth, sample size, error rate, and false positive rate, we used 
a simulated multi-sample caller that calculated the power of detecting a singleton at a site from 
the likelihood of calling the variant across 200,000 simulations. We validated these results using 
simulations from real-data, where we down-sampled from deeply sequenced genome and exome 
samples and, for each sample size and read depth combination, assessed our ability to detect 
previously called singletons. For a more detailed explanation of this part of our analysis, refer to 
our companion paper for binary traits.42 We chose parameter settings for our computational 
simulations where results closely mimicked empirical estimates and used these results for our 
analysis of association study power across a broad range of sample sizes, depths, and cost 
models. 
 
Power to Detect Association 
We assumed a model where the trait value is dependent on burden of singletons in a region, at 
significance level alpha = 2.5x10-6, corresponding to the analysis of ~20,000 independent gene 
regions. We assumed the data follow a simple linear regression model: 
€ 
yi = β0 + β1xi +ε i, ε i ~
iid
N 0,σ e2( )  
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where, for the ith individual, yi is the phenotype value, xi is the number of singletons in a gene, 
and εi is the error term. In this model, β0 represents the average trait value for an individual with 
no singleton variants in the gene and β1 represents the effect size, the change in the trait value for 
each additional singleton present in the gene for an individual. Since the power of association is 
dependent solely on the slope parameter (β1), we fixed β0 as 0 for our data generation. We 
allowed β1 to vary from 0.5 to 3. 
 
We modeled X following a Poisson(p) distribution, where the rate p is the population frequency 
of singletons per person per gene. In our companion paper for a similar analysis for binary traits, 
we estimated that singletons occur at a rate of 0.0079 per gene per person across the whole 
genome, assuming 20,000 genes.42 However, this rate may vary when looking at specific genes – 
it is reasonable to assume that longer genes may have higher rates of occurrence. We, therefore, 
considered rates from 0.001 to 0.01 per gene per person to account for most situations.  
 
The trait value given the number of singletons in a gene (Yi|Xi) follows a N(β0+β1xi, σe2) 
distribution. For ease of simulations, we assumed that Y is standardized so the total phenotypic 
variance, σp2, is 1. The variance of the error term can be calculated as: 
€ 
σp
2 =Var Y( ) =Var β0 + β1X +ε( ) = β12 ⋅ Var X( ) +Var ε( )
⇒1 = β12p +σe2
⇒σe
2 =1− β12p
 
 
For each simulation, we set the sample size (N), read depth (d), population frequency of 
singletons (p), and effect size (β1). For each individual, we sampled Xi~Poisson(p) and 
Yi|Xi~N(β0+ β1Xi, 1-(β1)2p). To account for uncertainty regarding the true number of singletons, 
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we adjusted Xi to determine the number of singletons detected for the ith individual, Zi. We first 
generated the number of singletons present for the ith individual that are correctly detected Ti~ 
Bin(Xi, s), where s is the sensitivity for detecting singletons given the depth and sample size. We 
also generated the number of false positive singletons for the ith individual, Fi~Poisson(γ/N), 
where γ is the false positive rate for detecting singletons. We adjusted by N to approximate the 
number of false positives in a single individual rather than across the sample. Zi is the sum of 
these quantities. 
 
Using the generated data, we fit a simple linear regression on Y using Z and assessed β1 for 
significance. We repeated this for 5000 replicates. Power was estimated as the fraction of 
simulations where β1 was significant out of the total number of replicates. 
 
Our goal was to identify the optimal study design in terms of sample size and depth of coverage, 
so we were interested in determining the depth at which power is maximized. Since power 
cannot increase beyond 100%, it is sometimes impossible to distinguish which of several depths 
results in the largest power if all have near 100% power. Therefore, we calculated the non-
centrality parameter for a linear regression F-test43:  
€ 
λ =
β1
2 (zi − z )2i=1
n
∑
σZe
2  
where σ2Ze= 1-(β1)2Var(Z)= 1-(β1)2[Var(T)+Var(F)]= 1-(β1)2[sp+γ/N]. As we are only interested 
in the slope term, we can use the non-centrality parameter for a t-test, which is the square root of 
the above term. 
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Results 
Sensitivity to Detect Singletons 
Our simulations show that sensitivity to detect singletons increases as coverage increases, until 
~25x, beyond which increasing depth further has little effect on power. This pattern holds for 
both fixed sample size and fixed sequencing capacity (where sample size decreases as coverage 
increases). For a fixed sample size of 100 individuals, empirical estimates resemble simulation 
estimates for a sequencing error rate of e=0.01 with a false positive rate of γ=0.001, though 
computational sensitivity estimates are lower than estimates using real data for lower depths and 
higher than estimates using real data at higher depths. For a more detailed explanation of this 
part of our analysis, refer to our similar analysis for binary traits.42  
 
Power to Detect Association 
We first considered a scenario with fixed cost (sample size and depth vary inversely of each 
other) with no extra cost of library/sample preparation (c=0). As depth increases, power 
increases until a threshold is reached. Beyond this depth threshold, a further increase in coverage 
results in a decrease in power. For example, sequencing 20,000 samples at 5x provides 42.94% 
power, sequencing 8,333 samples at 12x provides 80.74% power, and sequencing 2,000 samples 
at 50x provides only 7.52% power for population frequency of singletons 0.008 and effect size 
0.8. The magnitude of the power to detect association depends on the combination of the effect 
size (β1) and the population frequency of singletons (p). 
 
As the effect size increases, power increases, holding other parameters constant (see Figure 
III-1). For example, for a sample size of 8,333 at 12x coverage with a population frequency of 
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singletons of 0.008 and an effect size of 0.5, the power of an association study is 13.90%. When 
the effect size is increased to 0.7, the power increases to 59.14%, and, when the effect size is 
further increased to 1, the power increases to 98.02%. 
 
Similarly, as the population frequency of singletons increases, power also increases, holding 
other parameters constant (see Figure III-2). For example, sequencing 8,333 samples at 12x 
coverage with an effect size of 1 and a population frequency of singletons of 0.001 per gene per 
person provides 2.00% power. When frequency of singletons increases to 0.005, power increases 
to 77.08%, and, when singleton frequency is increased further to 0.01, power increases to 
99.84%. 
 
Power calculated through the average non-centrality parameter across replicates follows a similar 
pattern as empirical power (see Figure III-3). For a sequencing capacity of 100,000x, the 
difference in power estimates has a mean of 0.48% (with a standard deviation of 2.76%). We 
determined the depth at which the non-centrality parameter is maximized for each combination 
of parameters. As sequencing capacity increases, maximum NCP increases (see Figure III-4). As 
relative cost of library and sample preparation increases, maximum NCP decreases (see Figure 
III-5). When either total sequencing capacity or c increases, the point at which NCP is 
maximized shifts to a higher depth. For c=0, NCP is maximized at 11-12x; for c=5, NCP is 
maximized at 12-14x; and for c=20, NCP is maximized at 15-16x. With increasing per sample 
preparation costs, it is advantageous to sequence fewer individuals at higher depth. For 
sequencing capacity=50,000x, NCP is maximized at 11-15x; for sequencing capacity=100,000x, 
NCP is maximized at 12-15x; and, for sequencing capacity=200,000x, NCP is maximized at 12-
3737 
16x. With increasing total sequencing capacity, the overall sample size increases and a slight 
increase in sequencing depth is needed to accommodate the greater stringency needed to 
maintain low false positive rates in variant calling. This point does not vary much with effect 
size or population frequency of singletons. 
 
For fixed sample size, increasing depth does not always result in an increase in power (see 
Figure III-6). At low coverage, increasing depth increases power substantively. However, after a 
threshold is reached, power remains relatively constant. For instance, for an effect size of 0.7 and 
a population frequency of singletons of 0.008, sequencing 10,000 samples provides 57.62% 
power at 10x, 92.72% power at 25x, 93.36% power at 35x, and 93.36% power at 50x. Regardless 
of the parameter values examined, NCP is maximized by 35x, with 99% of maximal NCP 
occurring by 24x. 
 
Discussion 
We set out to compare low, intermediate, and deep sequencing strategies for sequencing studies 
exploring the association of singleton variants with quantitative traits. We found that power is 
never large unless effect size or frequency of singletons is large. If cost is fixed so sample size 
and depth vary inversely, power decreases as depth increases beyond 11-16x. Even for fixed 
sample size, increasing coverage beyond 24x has little effect on power. Therefore, we believe it 
will often be better to sequence larger samples at lower coverage rather than increasing coverage 
in smaller samples when searching for singletons associated with quantitative traits. We 
recommend increasing coverage beyond 16x only if sample size is restricted or reasons other 
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than genetic association studies can justify the advantages of sacrificing increased sample size in 
lieu of more complete sequencing of each individual. 
 
While varying effect size and population frequency of singletons varies the power to detect an 
association, the read depth and sample size combination that maximizes power (for a fixed cost) 
remains constant. Consider two scenarios. In the first, we have an effect size of 0.7 and a 
population frequency of singletons of 0.007. In the second, we have an effect size of 1 and a 
population frequency of singletons of 0.009. In both situations, assume a total sequencing 
capacity of 100,000x with intermediate library/sample preparation costs (c=5). The first scenario 
attains a maximum power of 20.67% (NCP = 3.89); the second reaches a maximum power of 
94.76% (NCP = 6.34). Both situations attain maximal power at a depth of 14x (with 5,263 
samples). This suggests that deep sequencing is not justified for detecting rare variant 
association, irrespective of trait or gene under study. While power may be low, increasing 
coverage beyond a threshold at 11-16x will not increase power if it requires a decrease in sample 
size.  
 
Of the parameters we considered, only the cost of library and sample preparation changed the 
depth required to maximize association study power, though this optimal depth remained 
between 11-16x. For larger library and sample preparation costs, the optimal depth increases 
slightly. For no extra cost of library/sample preparation (c=0), the ideal depth is 11-12x; for a 
moderate cost of library/sample preparation (c=5), the ideal depth is 12-14x; and when the cost 
of library/sample preparation is high (c=20), the ideal depth is 15-16x. When there is an 
increased penalty for increasing sample size rather than increasing coverage in the current 
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sample, a slightly deeper coverage is ideal to compensate for this penalty. For very large studies, 
the ideal depth shifts to slightly larger depths. For example, when the total sequencing capacity is 
50,000x, the ideal depth is 11-15x per genome; when this increases to 100,000x, the ideal depth 
is 12-15x per genome; and, for sequencing capacity of 200,000x, the ideal depth is 12-16x per 
genome. This increase in per genome depth allows variant calling to become more stringent as 
sample size increases (there are more opportunities for false positive calls as more genomes are 
sequenced). 
 
We explored effect sizes ranging from 0.5 to 3 in order to assess power in a variety of situations. 
Our analysis shows that, for really rare mutations, there is often insufficient power to be able to 
successfully detect an association between the number of singletons in a gene and a trait value 
for small to moderate effect sizes and a low frequency of singletons in a gene.  It is only possible 
to detect an association if the effect size is large or the population frequency of singletons in a 
gene is large.  We found that, while association study power increases as effect size increases, 
the depth at which power is maximized is unaffected by effect size modeled. 
 
In summary, despite the benefits of deep sequencing in locating more rare variants per 
individual, a preferable design for identifying very rare variants associated with quantitative 
traits is to increase sample size at lower depths. We conduct a similar analysis for binary traits in 
a companion paper.42 Our simulations focused on SNPs, although it is important to consider 
other types of variants such as insertions and deletions to further our understanding of the cause 
of disease. Since these non-SNP variants are, typically, more difficult to detect than SNPs, a 
4040 
greater depth may be required to maximize the power of association.38 A greater sequencing 
effort may be required to increase depth of coverage without decreasing sample size. 
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Figures and Tables 
Figure III-1. Association study power by read depth for constant cost for different effect 
sizes 
Fixed sequencing capacity of 100,000x with no extra cost of library/sample preparation (c=0) 
and population frequency of singletons 0.008 
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Figure III-2. Association study power by read depth for constant cost for varying 
population frequency of singletons 
Fixed sequencing capacity of 100,000x with no extra cost of library/sample preparation (c=0) 
and effect size 1. 
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Figure III-3. Empirical power by read depth for fixed sequencing effort compared with 
power calculated via NCP 
Fixed sequencing capacity of 100,000x with no extra cost of library/sample preparation (c=0), 
effect size 1, and population frequency of singletons 0.008. 
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Figure III-4. Association study power and NCP by read depth for different total costs  
Effect size =1; population frequency of singletons = 0.008; no library/sample preparation cost 
(c=0). 
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Figure III-5. Association study power and NCP by read depth for different library/sample 
preparation costs 
Sequencing capacity = 100,000x; effect size = 1; population frequency of singletons = 0.008. 
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Figure III-6. Association study power by read depth for fixed sample size 
Effect size = 0.7; population frequency of singletons = 0.008. 
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CHAPTER IV. Rapid Genotyping of Large Deletions from Next-Generation Sequencing 
Data3 
 
Abstract 
Many diseases, particularly psychiatric disorders such as schizophrenia and autism, have been 
associated with copy number variants. Detecting such variants is an important step in 
determining associations with diseases. Historically, this has been accomplished using array-
based methods, but these do not typically allow for any other type of analysis to be performed 
from the resultant data. As sequencing costs decrease, it is increasingly desirable to use sequence 
data to assess copy number. There are several existing methods that implement approaches using 
sequence data, but most analyze samples individually. We developed a method that leverages 
population data across multiple individuals to determine copy number within a particular region, 
focusing specifically on number of reads mapped to the region. We tested our method using the 
1000 Genomes Project Phase 1 samples and list of deletion regions. We were able to successfully 
identify 1,297 regions with easily distinguishable deletions, where each region has a mean 
accuracy of 95.49% (standard deviation of 8.16%) and a median of 97.67%. We also 
implemented our method in other samples, using this same list of regions. For AMD, GECCO, 
and Sardinia samples, we identified 935, 1,943, and 747 regions likely to encompass deletions, 
respectively. Our method is easy to use, fast, and accurate in calling deletions in regions 
                                                
3 Rashkin, S., Blackwell, T., and Abecasis, G. (In preparation). Rapid Genotyping of Large Deletions from Next-
Generation Sequencing Data. 
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identified to have distinguishable deletions. Other regions likely require inclusion of information 
beyond mapped read counts or other, more complicated, methods. 
 
Introduction 
Copy number variants (CNVs) are segments of the genome where the number of copies varies 
between individuals. Typically, an individual has two copies of the entire genome: one 
maternally inherited copy and one paternally inherited copy. However, if there is a deletion, 
there can be fewer than two copies. Similarly, more copies can arise if there is a duplication or 
insertion. CNVs are longer than indels, ranging from approximately 100 bps to several thousand 
kbs. Copy number variation at some regions has been associated with susceptibility or resistance 
to a variety of diseases.19 In particular, CNVs have been shown to be associated with psychiatric 
disorders, including schizophrenia and autism.18-20 Detecting CNVs has, therefore, become an 
increasingly important area of research.  
 
An important step in determining the association between CNVs and phenotypes of interest is to 
locate regions where copy number variation exists as well as the number of copies of each region 
that an individual possesses. Many studies have been conducted using microarray-based methods 
to locate CNVs.19; 20 However, with the decreasing cost of genome sequencing, the amount of 
sequencing data available is increasing, and these data can be useful in determining CNVs, while 
allowing for other types of analyses simultaneously. Some recent studies have used sequencing 
information in order to locate regions of varying copy number.19; 44 These methods consider at 
least one aspect of sequencing data in assessing copy number: (1) read depth analysis, which 
compares depth of coverage in a window to average depth to determine copy number; (2) read 
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pair analysis, which involves analysis of abnormally mapping pairs of reads; (3) split-read 
analysis, which assesses gapped sequence alignment; and (4) sequence assembly, which allows 
for structural variation detection.19; 21; 38 While these methods all involve analysis of sequence 
data, most still analyze one genome at a time. One notable exception is Genome STRiP, which 
leverages population-level data into identification of deletions.21; 44  
 
We developed a fast and simple method that works on sequence data within a specific region of 
interest. Focusing only on detecting deletions in key regions, we used sequencing data, 
specifically the number of reads mapped to a region, in order to predict CNVs via an 
expectation-maximization (EM) algorithm. We tested our method on the 1000 Genomes Project 
list of deletion regions using Phase 1 samples and successfully identified 1,297 regions (out of a 
total 13,973), with each region having a mean accuracy of 95.49% (standard deviation of 8.16%) 
and a median accuracy of 97.67%. Implementing our method on age-related macular 
degeneration (AMD)45, Genetics and Epidemiology of Colorectal Cancer Consortium 
(GECCO)31, and Sardinia46 samples, we identified 935, 1,943, and 747 regions likely to have 
deletions, respectively. While our method might miss some deletion regions, these regions likely 
require more complicated detection methods, making them slower or more cumbersome to use. 
 
Methods 
It can be assumed that read depth in a region can be associated with the number of deletions at 
the region in question. As copy number decreases, read depth should also decrease. We 
measured an individual’s read depth for each region as the number of reads mapped to the 
5050 
region, adjusted by the total number of reads mapped for the individual. We further adjust read 
counts for a region by the mean read count across individuals for that region. 
 
If there are two copies of the region, we can expect to have a high read depth, whereas we expect 
very low read depth if there are two deletions. Read depth can be modeled using a Gaussian 
mixture distribution:  
€ 
di ~ p0 ⋅ N µ0,σ 02( ) + p1⋅ N µ1,σ12( ) + p2 ⋅ N µ2,σ 22( ) 
where di is the adjusted number of reads mapped to a region for the ith individual, μj represents 
the mean of the distribution component for j number of deletions (0, 1, 2), σj represents the 
standard deviation of the distribution component for j number of deletions, and pj represents the 
probability of having j number of deletions. 
 
To reduce the parameters being estimated, we relate the means of the three distributions to each 
other, based on the hypothesis: for an individual with two copies of the region, read depth is 
high; for an individual with no copies of the region, read depth is minimal; and, for an individual 
with one copy of the region, read depth falls in between these values. For this scenario, we set: 
€ 
µ0 = µ
µ1 = µ + Δ
µ2 = µ + 2Δ
 
where μ is the mean for the read count distribution for zero deletions and Δ is the difference in 
means between the groups. We further reduced the number of parameters by assuming each 
component of our mixture model has the same variance. Additionally, we assumed that the 
presence of a deletion is in Hardy-Weinberg Equilibrium (HWE), so the three probabilities can 
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be related to each other, so we only need to estimate one parameter, pdel, the probability of there 
being a deletion. Therefore, our model becomes: 
€ 
di ~ (1− pdel )2 ⋅ N µ,σ 2( ) + 2pdel (1− pdel )⋅ N µ + Δ,σ 2( ) + pdel2 ⋅ N µ + 2Δ,σ 2( ) 
 
We implemented an expectation-maximization (EM) algorithm to predict the maximum 
likelihood estimates for the mixture distribution and used these estimates to predict the number 
of deletions for each individual at each region. The EM-algorithm is a method of estimating 
parameters when there is missing data; here, the number of deletions is unknown. It is an 
iterative procedure resulting in the maximum likelihood estimates of all parameters. Since it is 
only guaranteed to find the local maximum and it can be sensitive to initial parameter values, we 
used multiple initialization values for each parameter (randomly selected within range of data) 
and kept the estimates resulting in the highest likelihood.  
 
More specifically, for a set of observed data D that follows a statistical model (here, we assume 
di are independent, identically distributed and follow the mixture distribution described above), a 
set of unobserved data Z (here, zi is the number of deletions for each individual), and a vector of 
parameters θ (here, θ=(pdel, μ, Δ, σ2)), the EM algorithm identifies the parameter estimates that 
maximize the likelihood function, L(θ;D,Z). The EM algorithm consists of two steps that are 
performed iteratively until parameter estimates converge.  
 
In the expectation (E) step, we calculate Q(θ|θ(r)), the expected value of the log likelihood with 
respect to Z given D and the current parameter estimates θ(r), where r is the step number: 
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€ 
Q θ θ (r )( ) = EZ |d ,θ ( r ) log L θ;D,Z( )[ ]
∝ log p j(r)( )E I Zi = j( )D,θ (r)i=1
n
∑⎡ ⎣ ⎢ 
⎤ 
⎦ ⎥ +
−1
2 log σ j(r)( )
2
− 12σ j2 di − µ j
(r)( )
2⎡ 
⎣ ⎢ 
⎤ 
⎦ ⎥ i=1
n
∑ E I Zi = j( )D,θ (r)[ ]⎧ ⎨ ⎩ 
⎫ 
⎬ 
⎭ j=0
2
∑
 
We can simplify this equation to calculating the following quantities: 
€ 
E I Zi = j( )D,θ (r )[ ] = P Zi = j D,θ (r )( )
=
p j(r ) f di;µ j(r ),σ j(r)( )
p j(r ) f di;µ j(r ),σ j(r)( )j=0
2
∑
= Tj,i(r+1)
E I Zi = j( )D,θ (r )i=1
n
∑⎡ ⎣ ⎢ 
⎤ 
⎦ ⎥ = Tj ,i
(r+1)
i=1
n
∑
 
where the first is calculated for each individual i and group j, and the second is the summation of 
the first quantity across all individuals for each group j. 
 
The maximization (M) step finds the parameter values that maximize Q(θ|θ(r)): 
€ 
θ (r+1) = argmax
θ
Q θ θ (r )( )  
We can simplify this to the following expressions for each parameter: 
€ 
pdel(r+1) =
T1,i(r+1)i=1
n
∑ + 2 T2,i(r+1)i=1
n
∑
2n
µ(r+1) = d − Δ(r+1)⋅ y (r+1), where y (r+1) =
T1,i(r+1) + 2⋅ T2,i(r+1)( )i=1
n
∑
n
Δ(r+1) =
Tj,i(r+1) j − y (r+1)( ) di − d ( )j =0
2
∑i=1
n
∑
Tj,i(r+1) j − y (r+1)( )j =0
2
∑i=1
n
∑
σ (r+1) =
Tj,i(r+1) di − µ j(r+1)( )
2
j =0
2
∑i=1
n
∑
n , where µ j
(r+1) = µ(r+1) + j⋅ Δ(r+1)
 
 
We used the Kullback-Leibler (KL) distance between the null model of a single normal 
distribution and the estimated mixture model to assess whether our method is likely to be able to 
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accurately call deletions. The KL distance between distributions P and Q can be conceptualized 
as the information lost when using Q to approximate P and is calculated as: 
€ 
DKL P Q( ) = p(x)log
p(x)
q(x) dx−∞
∞
∫  
where P is the null distribution and Q is the mixture distribution. Small values of KL distance 
indicate that Q, the estimated mixture distribution, is similar to P, the null distribution of a single 
normal distribution. 
 
We first tested our method using 1,072 samples (average depth 11.36x) from the 1000 Genomes 
Project Phase 1 data and associated list of deleted regions.47 We restricted our analysis to the 
13,973 autosomal regions. We used these data to determine the value of KL distance that allows 
for detecting regions where deletions are present in some individuals and accurately genotyping 
each individual. We then applied our method to three other datasets: 1968 AMD samples 
(average depth ~5x)45, 2975 samples (average depth ~13x) from the Genetics and Epidemiology 
of Colorectal Cancer Consortium (GECCO)31, and 3441 Sardinian samples (average depth 
~4x)46. 
 
Results 
Our method works well to detect deletions in regions, especially for regions where the read count 
distributions for each number of deletions are well separated (see Figure IV-1). For a KL 
distance threshold of 0.3, our method identifies 1,853 regions likely to have deletions (see Table 
IV-A). Comparing deletion calls with those from the 1000 Genomes Project, these regions have a 
mean concordance of 75.12% (standard deviation of 39.12%) and a median of 95.62% (see Table 
IV-A).  
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Since we anticipate very few reads to be mapped to a region when there is a homozygous 
deletion, we expect the estimated mean for this group to be close to 0. Therefore, we further filter 
regions to exclude those where the mean for this group is further than two standard deviations 
away from zero. After applying this filter, we identify 1,297 regions that have a mean 
concordance of 95.49% (standard deviation of 8.16%) and a median of 97.67% (see Table IV-B). 
Furthermore, only 15 regions have a concordance below 80% (136 below 90%). For most of 
these regions, the read count distributions either are very overlapped (see Figure IV-2) or do not 
follow the distribution we expect (see Figure IV-3). 
 
In regions where the read count distributions for each number of deletions are overlapped, some 
genotype calls are incorrect or ambiguous (see Figure IV-4).  We attempted to resolve this 
uncertainty by performing genotype refinement via Beagle.48 Use of this genotype refinement 
tends to improve genotype accuracy, especially in regions where the read count distributions are 
overlapping (see Figure IV-4). While some regions do not show an improvement after genotype 
refinement, most show moderate increases in concordance (see Figure IV-5). 
 
We applied our method with the same filters for the same list of 13,973 deletion regions to three 
other datasets to identify regions likely to have deletions in these samples. For each of these 
datasets, our method identified an overlapping, but not identical, list of regions where deletions 
are likely (see Figure IV-6). Comparing the list of 1,297 regions identified by our method in the 
1000 Genomes Project Phase 1 samples with the regions identified in other datasets, 454 regions 
are only identified in the 1000 Genomes samples. Our method identifies 935 regions in the AMD 
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samples, 77 of which are uniquely identified in these samples. Our method identifies 1,943 
regions, where 1,023 regions are not identified in any other dataset. While having the largest 
sample size (3,441 individuals), our method identifies the fewest number of regions in the 
Sardinia samples: 747 regions, with only 36 uniquely identified in these samples. There are 557 
regions our method identifies as likely to have deletions in all four datasets. 
 
Discussion 
We developed a novel method for detecting deletions from sequence data by leveraging 
information across multiple samples simultaneously. Our method is fast, easy to use, and 
accurate. Using the 1000 Genomes Project Phase 1 samples and list of deletion regions, our 
method identified 1,297 regions, with each region having a mean accuracy of 95.49% (standard 
deviation of 8.16%) and a median of 97.67%. Implementing our method on AMD, GECCO, and 
Sardinia samples, we identified 935, 1,943, and 747 regions likely to have deletions, 
respectively. While our method might miss some deletion regions, these regions likely require 
more complicated detection methods, making them slower or more cumbersome to use. 
 
Our method runs quickly. Collecting metadata for each region for each individual is the rate-
limiting step, compared to running our deletion caller. For 100 regions in a single sample 
processed on a single CPU, collecting the metadata takes approximately 5 minutes. Once the 
metadata are collected, implementing our deletion caller for 100 regions in a sample of 100 
individuals takes approximately 10 seconds on a single CPU, running a single region at a time. 
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Since our method runs quickly, even though it may miss some deletion regions, it provides a 
useful step in an analysis where it is important to identify regions where deletions are likely. In 
particular, our method allows for a quick determination of deletion calls within specific regions 
of interest, without identifying particular breakpoints. In addition, its speed allows for a quick 
overview of specific regions and whether they are likely to contain deletions in a specific sample 
without committing to a more complicated, and time consuming, analysis. 
 
Our method identifies the fewest number of deletion regions in the Sardinia data. While having 
the largest sample size (3441 individuals), these samples have the lowest average depth. Since 
our method compares read counts within a region, the deeper the coverage, the better it will be 
able to make comparisons. 
 
Our method should work for all types of sequencing data, including exome data, but our analysis 
here focused on whole genome sequencing data. Further testing is necessary to assess method 
performance with exome data. Additionally, our current method only allows for detection of 
deletions within a specified region. Further work is necessary to include detection of insertions. 
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Figures and Tables 
Figure IV-1. Example of region where distributions are well-separated 
Region located at 1:152555542-152587742 
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Table IV-A. Region concordance by KL threshold 
 
KL Threshold # Regions Mean Concordance (SD) (%) Median Concordance (%) 
0.3 1853 75.12 (39.12) 95.62 
0.35 1436 80.95 (34.94) 96.74 
0.4 1145 86.34 (23.10) 97.29 
0.45 918 90.71 (23.10) 97.67 
0.5 761 92.87 (19.41) 97.95 
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Table IV-B. Region concordance by KL threshold for regions where μ2-2σ<0 
 
KL 
Threshold 
Number 
of 
Regions 
Mean 
Concordance 
(SD) (%) 
Median 
Concordance 
(%) 
# Regions where 
concordance 
<80% 
# Regions where 
concordance 
<90% 
0.3 1297 95.49 (8.16) 97.67 15 136 
0.35 1108 95.85 (7.94) 97.85 11 86 
0.4 954 95.97 (8.31) 97.85 9 62 
0.45 801 96.21 (8.24) 97.95 8 43 
0.5 680 96.53 (7.97) 98.04 7 27 
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Figure IV-2. Example of regions where distributions are very overlapped 
Region located at 7:8698628-8698846 
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Figure IV-3. Example of a region where read counts do not follow expected distribution 
Region located at 1:1564801-1568200 
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Figure IV-4. Example of region where distributions are overlapping 
Region located at 21:15460780-15461864 
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Figure IV-5. Concordance after Genotype Refinement vs. Original Concordance 
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Figure IV-6. Venn diagram comparing lists of regions identified in each dataset 
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CHAPTER V. Discussion 
 
While thousands of loci have been associated with complex diseases and traits, much is still 
unknown about the biology of disease. One possible reason is that much of genetic association 
studies has focused on common SNPs. Therefore, in this dissertation, we described methods that 
will aid in the design and analysis of complex traits using sequence data by allowing for 
improved assessments of other types of variants to disease, particularly rare variants and copy 
number variants. 
 
In Chapters II and III, we assess different study designs to determine what analysis plan (deep, 
intermediate, or low coverage sequencing) is best for studying very rare variants. This will aid in 
future endeavors to design studies with goals of identifying rare variants associated with either 
discrete or quantitative traits. We showed that, when cost is fixed so read depth and sample size 
vary inversely, power to detect association between a singleton variant and a trait decreases as 
coverage is increased beyond a threshold (15-20x for discrete traits, 11-16x for quantitative 
traits). We recommend increasing coverage beyond this threshold only if sample size is restricted 
or reasons beyond genetic association studies justify decreasing sample size in favor of a more 
complete sequencing of each individual. 
 
In Chapter IV, we describe a novel method for detecting deletion regions from sequence data by 
leveraging information across samples.  This allows for determining deletion regions, which is 
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useful in downstream analysis, quickly, easily, and accurately, without the added expense of an 
extra assay. While our method might miss some deletion regions, these regions likely require 
more complicated detection methods. Our method’s speed allows for a quick overview of 
specific regions to determine which ones are likely to contain deletions for a sample of 
individuals before committing to a more detailed and time consuming analysis. 
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